While Ian Moss' practice is predominantly concerned with patent litigation, he also advises clients in relation to other IP matters such as licence negotiation and drafting, settlement, and other commercial agreements.
Ian acts for clients involved in a variety of industries, including the electronics, medical devices and pharmaceutical sectors. In the electronics sector, Ian advises clients on both assertion of patents and defence against infringement claims in disputes concerning standard essential and non-essential technologies. Major patent disputes often involve international clients litigating in several jurisdictions and this is undoubtedly the case with Ian's practice.
Working on such wide ranging international disputes has given Ian extensive experience with international clients and the demands of coordinating transnational legal teams from different jurisdictions. Ian's experience includes proceedings in the Intellectual Property and Enterprise Court, the High Court (Patents Court) and the Court of Appeal in the UK and before the Technical Boards of Appeal of the European Patent Office.
Ian joined Hogan Lovells as a trainee in 2011 and had seats in the IP, general litigation and finance teams before qualifying and joining the IP department in 2013. During his traineeship, Ian spent 9 months on client secondment allowing him to develop a deep understanding of what clients really need from their external legal teams. Before joining Hogan Lovells, Ian studied Developmental Biology at Edinburgh University and obtained a 1st class degree with honours. Following qualification, Ian completed Oxford University's Post-graduate Diploma in Intellectual Property Law.
'MIP Global Awards 2015 European Patent Firm – Contentious'
'A fantastic team - very organised and they have excellent technical understanding'
Areas of Focus
Acting for a major multinational engineering group in breach of confidence / trade secrets litigation.
Acting for an international medical devices manufacturer in proceedings in the UK and EPO relating to hydrophilic catheter products.
Acting for HTC in UK litigation against IPCom, a non-practising entity, in relation to a potentially standard essential patent.
Acting for a major innovator pharmaceuticals company in relation to potential invalidity proceedings.
Acting for a major electronics company in multi-jurisdictional patent litigation involving both standards essential and non-essential patents.
Acting for Novartis in relation to the IP aspects of its acquisition of GSK's oncology business for a value of up to US$16bn.